Literature DB >> 35403177

Effectiveness of Amplified Natural Killer (ANK) Therapy for Adult T-cell Leukemia/Lymphoma (ATL) and Future Prospects of ANK Therapy.

Kenjiro Nagai1,2, Sho Nagai1.   

Abstract

Amplified Natural Killer (ANK) therapy is modified to increase the safety and efficacy of the original (LAK) immunotherapy. It is a method of removing natural killer (NK) cells from the patient's own blood, culturing and amplifying the NK cells, specifically increasing their ability to attack cancer and returning them for treatment. It is generally effective against all cancers. The two cases presented here and the other treated cases show that ANK therapy is very safe and effective against ATL. Further research suggests that ANK therapy, rather than chemotherapy, is likely to be the first-line therapy for ATL. In addition, low activity of NK cells means accumulation of bacterial load. Therefore, ANK therapy with high doses of activated NK cells may be effective not only for ATL and cancer, but also for patients with chronic bacterial and viral infections.

Entities:  

Keywords:  Adult T-cell leukemia; Amplified natural killer cell therapy; HTLV-1-Associated branching bronchioalveolar disorder; Lymphokine-activated killer cell immunotherapy

Year:  2022        PMID: 35403177      PMCID: PMC8986168     

Source DB:  PubMed          Journal:  Cancer Med J


  17 in total

1.  Uveitis associated with human T-cell lymphotropic virus type I.

Authors:  M Mochizuki; T Watanabe; K Yamaguchi; K Yoshimura; S Nakashima; M Shirao; S Araki; K Takatsuki; S Mori; N Miyata
Journal:  Am J Ophthalmol       Date:  1992-08-15       Impact factor: 5.258

2.  Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma.

Authors:  Takatoshi Shimauchi; Kenji Kabashima; Daiki Nakashima; Kazunari Sugita; Yoko Yamada; Ryosuke Hino; Yoshiki Tokura
Journal:  Int J Cancer       Date:  2007-12-15       Impact factor: 7.396

3.  Lymphokine-activated killer cells: a new approach to immunotherapy of cancer.

Authors:  S Rosenberg
Journal:  J Natl Cancer Inst       Date:  1985-10       Impact factor: 13.506

4.  Galectin-9 as a Predictive Marker for the Onset of Immune-Related Adverse Effects Associated with Anti-CCR4 MoAb Therapy in Patients with Adult T Cell Leukemia.

Authors:  Tareg Omer Mohammed; Haorile Chagan-Yasutan; Yugo Ashino; Wakana Nakayama; Yayoi Takahashi; Taizo Shimomura; Tetsuhiro Fujimoto; Yuko Watanabe; Toshiro Niki; Hitoshi Suzushima; Toshio Hattori
Journal:  Tohoku J Exp Med       Date:  2017-03       Impact factor: 1.848

5.  Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15.

Authors:  J Dunne; S Lynch; C O'Farrelly; S Todryk; J E Hegarty; C Feighery; D G Doherty
Journal:  J Immunol       Date:  2001-09-15       Impact factor: 5.422

6.  Clinical diversity in adult T-cell leukemia-lymphoma.

Authors:  K Takatsuki; K Yamaguchi; F Kawano; T Hattori; H Nishimura; H Tsuda; I Sanada; K Nakada; Y Itai
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

7.  Clinical similarities and differences between human T-cell lymphotropic virus type 1-associated bronchiolitis and diffuse panbronchiolitis.

Authors:  Jun-ichi Kadota; Hiroshi Mukae; Takeshi Fujii; Masafumi Seki; Kazunori Tomono; Shigeru Kohno
Journal:  Chest       Date:  2004-04       Impact factor: 9.410

8.  Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2.

Authors:  T Ishikawa; M Imawari; T Moriyama; S Ohnishi; N Matsuhashi; G Suzuki; F Takaku
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

9.  Activated human primary NK cells efficiently kill colorectal cancer cells in 3D spheroid cultures irrespectively of the level of PD-L1 expression.

Authors:  Pilar M Lanuza; Alan Vigueras; Sara Olivan; Anne C Prats; Santiago Costas; Guillermo Llamazares; Diego Sanchez-Martinez; José María Ayuso; Luis Fernandez; Ignacio Ochoa; Julián Pardo
Journal:  Oncoimmunology       Date:  2018-02-12       Impact factor: 8.110

10.  Can immune parameters be used as predictors to distinguish between pulmonary multidrug-resistant and drug-sensitive tuberculosis?

Authors:  Bayram Kiran; Tulin Cagatay; Philip Clark; Filiz Kosar; Penbe Cagatay; Sibel Yurt; Faruk Suzergoz; Ali Osman Gurol
Journal:  Arch Med Sci       Date:  2010-03-09       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.